[144] Incyte Genomics Inc SEC Filing
Incyte Genomics Inc (INCY) filed a Form 144 reporting a proposed sale of 277 common shares on 08/15/2025 through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of $24,046.37 and shows 195,276,145 shares outstanding, and the shares were acquired the same day via a stock option exercise with payment in cash.
The filing also discloses five recent sales by Sheila Denton within the prior three months: 1,795 shares on 06/03/2025; 599 on 07/02/2025; 3,330 on 07/15/2025; 785 on 07/16/2025; and 598 on 08/04/2025, with gross proceeds reported for each sale. The filer certifies no undisclosed material adverse information and the form identifies Morgan Stanley as broker of record.
- Required disclosure provided for proposed sale including broker, acquisition method, payment type, and aggregate market value
- Recent sales history disclosed for the past three months, enhancing transparency
- Insider selling activity by the same individual (multiple transactions totaling several thousand shares) could be viewed unfavorably by some investors
- Form lacks issuer identity details in the provided content (issuer address and SEC file number are not shown)
Insights
TL;DR Insider exercised options and plans a small secondary sale; recent insider dispositions are disclosed but represent a tiny fraction of outstanding stock.
The filing documents a routine Form 144 tied to a same-day stock option exercise and a proposed sale of 277 shares valued at about $24k. With 195.3 million shares outstanding, the planned sale is immaterial to capitalization. Recent sales by the same individual show ongoing liquidity events but no indication of company-level disclosure issues. For investors, these are compliance-level disclosures rather than signals of operational change.
TL;DR Form 144 appears complete for the transaction and includes required past three-month sales; signature and broker details are provided.
The form lists the broker (Morgan Stanley Smith Barney LLC), acquisition method (stock option exercise), payment type (cash), and aggregates recent dispositions by the seller, satisfying Rule 144 notice elements. The filer makes the standard representation regarding material nonpublic information. No procedural or disclosure deficiencies are apparent from the text provided.